Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.

European journal of clinical pharmacology - 1 Dec 2000

Scordo M G, Spina E, Romeo P, Dahl M L, Bertilsson L, Johansson I, Sjöqvist F

Abstract excerpt

OBJECTIVE: In order to evaluate whether poor metabolizers (PM) of debrisoquine are overrepresented among patients with acute dystonic reactions and chronic movement disorders associated with the administration of antipsychotic drugs, the CYP2D6 genotype was determined in schizophrenic patients. METHODS: Allele status for CYP2D6*3, CYP2D6*4, CYP2D6*5, and CYP2D6*6 as well as gene duplication was determined by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Alleles
Share to Antipsychotic Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Basal Ganglia Diseases

Share to Cytochrome P-450 CYP2D6

Share to Genotype

Share to Phenotype

Share to Schizophrenia

Source

Identifiers

PMID: 11214775
DOI: 10.1007/s002280000222

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.PMID 11214775Read ↗

Cyp2d6*3, *4, *5 and *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy.Semantic proximity Read ↗

Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype.Semantic proximity Read ↗

Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes.Semantic proximity Read ↗

CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.Semantic proximity Read ↗

Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia.Semantic proximity Read ↗

Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study.Semantic proximity Read ↗

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation CapacitySemantic proximity Read ↗

Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia.Semantic proximity Read ↗

CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.Semantic proximity Read ↗

CYP2D6 mutations and therapeutic outcome in schizophrenic patients.Semantic proximity Read ↗

Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implicationSemantic proximity Read ↗

Does the medication pattern reflect the CYP2D6 genotype in patients with diagnoses within the schizophrenic spectrum?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.